Table 3.
Odds of Positive Results on Both HBsAg and Anti-HBc Tests Versus Both Tests Negative in Univariate and Multivariable Logistic Regression Analyses
| Predictor | No. | % | Both HBsAg and Anti-HBc Positive (n = 25) |
|||
|---|---|---|---|---|---|---|
| Univariate Analysis* |
Multivariable Analysis |
|||||
| OR | 95% CI | OR | 95% CI | |||
| Age, years | 1.0 | 0.97 to 1.01 | ||||
| Mean | 48.8 | |||||
| SD | 11.0 | |||||
| Sex | ||||||
| Male | 20 of 914 | 2.2 | 2.8 | 1.0 to 7.5† | 7.4 | 2.0 to 27.0‡ |
| Female | 5 of 627 | 0.8 | Reference | Reference | ||
| Ethnicity | ||||||
| Hispanic | 3 of 204 | 1.5 | 4.3 | 1.0 to 19.4 | 4.5 | 1.0 to 20.7 |
| Black | 3 of 98 | 3.1 | 9.1 | 2.0 to 41.3‡ | 9.7 | 2.1 to 45.6‡ |
| Asian | 12 of 31 | 38.7 | 182.3 | 53.9 to 616.9§ | 270.8 | 65.4 to 1,109.0§ |
| Other | 3 of 49 | 6.1 | 18.8 | 4.1 to 86.6‡ | 13.0 | 2.6 to 64.6‡ |
| White | 4 of 1,159 | 0.4 | Reference | Reference | ||
| Residence | ||||||
| Outside United States | 2 of 59 | 3.4 | 2.2 | 0.5 to 9.7 | ||
| United States | 23 of 1,482 | 1.6 | Reference | |||
| HBV risk factors | ||||||
| Yes | 17 of 414 | 4.1 | 6.0 | 2.6 to 14.0§ | 3.9 | 1.4 to 10.5‡ |
| No | 8 of 1,127 | 0.7 | Ref. | Reference | ||
| Cancer type | ||||||
| Hematologic malignancy | 11 of 1,097 | 1.0 | 0.4 | 0.2 to 0.9† | 0.7 | 0.3 to 2.1 |
| Primary liver cancer | 3 of 21 | 14.3 | 6.2 | 1.6 to 24.3‡ | 8.3 | 1.5 to 46.3† |
| Solid tumor, excluding primary liver cancer | 11 of 423 | 2.6 | Reference | Reference | ||
| Chemotherapy type | — | |||||
| Rituximab | 6 of 709 | 0.9 | 0.5 | 0.2 to 1.8 | — | |
| Immunotherapy, excluding rituximab | 5 of 80 | 6.3 | 3.5 | 1.2 to 10.0† | — | |
| Chemotherapy/nonimmunotherapy | 14 of 752 | 1.9 | Reference | — | ||
NOTE. Model includes 1,541 patients who had either both tests positive (n = 25) versus both tests negative (n = 1,516). Age and residence variables were not entered in the multivariable model because their P > .20. Empty cells with dashes refer to variables not retained in the final step of the multivariable model because their P > .05.
Abbreviations: HBsAg, hepatitis B surface antigen; anti-HBc, antibody to hepatitis B core antigen; OR, odds ratio; SD, standard deviation.
P ≤ .20 for the following predictors in the univariate logistic regression model, which were entered into the multivariable model: sex, ethnicity, HBV risk factors, cancer type, and chemotherapy type. History of HBV infection was not entered into the model because of small numbers of patients without a history HBV infection but with positive HBsAg and anti-HBc test results.
P < .05.
P < .01.
P < .001.